Articles

Activity and novelty: Managing risk in drug discovery

COMPETITIVE PRESSURES and economic realities demand that pharmaceutical developers extract as much value as possible from drug discovery programs. Complicating this imperative are the seemingly endless paradigm shifts within discovery science. Although medicinal chemistry has always been part of the picture, over the last 20 years, the discovery model has evolved from pure med chem to incorporate varying components of computational chemistry, high-throughput methods and rational design. Today’s discovery programs are likely to employ all these methods.
| 6 min read

Competitive pressures and economic realities demand that pharmaceutical developers extract as much value as possible from drug discovery programs. Complicating this imperative are the seemingly endless paradigm shifts within discovery science. Although medicinal chemistry has always been part of the picture, over the last 20 years, the discovery model has evolved from pure med chem to incorporate varying components of computational chemistry, high-throughput methods and rational design. Today's discovery programs are likely to employ all these methods.

While the majority of small-molecule drug discovery efforts share the goal of identifying and promoting active compounds, programs may have any number of starting points. The high-throughput strategy, popular a decade ago and still predominant at many companies, relies on the synthesis or acquisition of large compound libraries and rapidly testing each molecule against appropriately designed in vitro screens. Large, chemically diverse libraries provide the most value in situations where drug target data is sparse, or where ligand classes remain undefined. Large libraries' varying degrees of specificity toward common target classes nevertheless represent a reasonable first-pass attempt to uncover activity, especially when a robust assay is already in place.

Molecular design techniques, which have proliferated of late, seek to reintroduce rational design into library generation. Most major pharmaceutical companies publish and speak extensively on their design efforts. In silico techniques have similarly emerged for virtually screening very large compound libraries. Drug firms' interest in molecular design suggests a small but growing disinclination to pin hopes of discovery success entirely on large, chemically diverse, synthesized compound libraries. The growing popularity of focused libraries supports this view.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.